Binds to specific E.G.F.R. mutants (T790M, L858R, and exon 19 deletions), which are more prevalent in non-small cell lung cancer (N.S.C.L.C.) following the first-line EGFR-TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.